Moderna, Inc. (MRNA) Latest Company News

Sep 17, 2026, 15:10 UTC
Moderna's stock price reached a four-week high, with its latest gain at 8%.
Source:
- benzinga.com
Sep 16, 2026, 18:30 UTC
The US Food and Drug Administration approved Moderna's mFLUSIVA, the first mRNA-based influenza vaccine, for adults aged 50 and older.
Source:
- futurity.org
Sep 14, 2026, 21:50 UTC
Moderna (MRNA) shares closed at $146.69, up 1.89% from the prior session, outperforming a 0.48% decline in the S&P 500, a 0.29% drop in the Dow and a 0.56% drop in the Nasdaq.
Source:
- ca.finance.yahoo.com
- zacks.com
Sep 14, 2026, 14:15 UTC
Moderna and Merck announced that a personalized mRNA cancer vaccine combined with an immunotherapy drug succeeded in a late-stage trial for skin cancer.
Source:
Sep 12, 2026, 18:45 UTC
Bloomberg announced the initial list of confirmed speakers for the eighth Bloomberg New Economy Forum, to be held in New Delhi from October 13 to 15, 2026, under the theme "A World in Play: Defining the New Levers of Power."
Source:
- indiacurrents.com
Sep 11, 2026, 15:56 UTC
Moderna shares jumped just over 8% on Friday, trading at $148.13 as of 11:45am ET, continuing a volatile stretch following a landmark Phase 3 cancer trial result announced in August.
Source:
- seekingalpha.com
Sep 4, 2026, 12:30 UTC
The UK Medicines and Healthcare products Regulatory Agency (MHRA) authorised Moderna's updated COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 XFG variant, for adults and children aged six months and above.
Source:
- pmlive.com
Aug 27, 2026, 19:59 UTC
Moderna announced that its upgraded COVID-19 vaccine is expected to be available in the coming days.
Source:
- finance.sina.cn
Aug 27, 2026, 11:20 UTC
Moderna announced a proposed private placement of $2.0 billion aggregate principal amount of Convertible Senior Notes due 2032, with an option for initial purchasers to buy up to an additional $300 million, to qualified institutional buyers.
Source:
Aug 10, 2026, 12:45 UTC
The U.S. Food and Drug Administration approved a new mRNA-based flu vaccine from Moderna for adults aged 50 and older.
Source:
Aug 6, 2026, 11:00 UTC
Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.
Source:
- globenewswire.com
Aug 6, 2026, 02:17 UTC
Moderna announced that its influenza vaccine MflusiVa will be available at select retailers in the coming weeks.
Source:
Aug 4, 2026, 15:00 UTC
Moderna Inc. has started a Phase 1 clinical trial of an experimental Ebola vaccine targeting the strain causing the outbreak in the Democratic Republic of Congo.
Source:
- bloomberg.com
- barrons.com
Aug 4, 2026, 15:00 UTC
Moderna announced the initiation of a Phase 1 clinical trial for its investigational mRNA vaccine mRNA-1469 against Bundibugyo ebolavirus, with first participants vaccinated in Canada.
Source:
Jul 31, 2026, 11:00 UTC
Moderna announced that its seasonal influenza vaccine candidate mFLUSIVA has an anticipated FDA approval decision date of August 5, 2026.
Source:
- accessnewswire.com
- techtimes.com
Jul 31, 2026, 11:00 UTC
Moderna reported second quarter 2026 financial results with revenue of $0.1 billion, a GAAP net loss of $0.8 billion, and GAAP EPS of -$1.97.
Source:
Jul 31, 2026, 11:00 UTC
Moderna announced that its norovirus vaccine candidate mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis and the company is preparing to enroll an additional cohort.
Source:
- accessnewswire.com
- zacks.com
Jul 16, 2026, 11:30 UTC
Arbutus Biopharma received a first payment from a settlement agreement with Moderna.
Source:
- globenewswire.com
Jul 9, 2026, 13:15 UTC
Moderna opens a new innovation centre in Harwell with a £1 billion UK R&D investment commitment over the next 10 years.
Source:
- gov.uk
Jul 9, 2026, 11:17 UTC
Moderna secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Source:
- reuters.com
Jul 8, 2026, 00:00 UTC
Michael McDonnell was appointed as a Class II director of Moderna, Inc. and a member of its Audit Committee, effective July 8, 2026.
Jun 29, 2026, 07:25 UTC
The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 that Moderna's mFLUSIVA (mRNA-1010) has a favorable benefit-risk profile for adults aged 50 and older.
Source:
- beincrypto.com
Jun 25, 2026, 18:31 UTC
The FDA advisory committee recommended Moderna's flu vaccine for approval.
Source:
- bloomberg.com
Jun 18, 2026, 20:00 UTC
The FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously in favor of the benefit-risk profile of Moderna's investigational seasonal influenza vaccine mRNA-1010.
Source:
Jun 17, 2026, 06:38 UTC
Moderna expressed interest in investing in production facilities in Germany, potentially acquiring plants that BioNTech plans to close.
Source:
- reuters.com
Jun 16, 2026, 12:37 UTC
Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises.
Source:
- reuters.com
Jun 2, 2026, 20:34 UTC
Moderna launched Moderna Direct, an eCommerce platform powered by FFF Enterprises, to provide an enhanced ordering experience for its customers.
Source:
- globenewswire.com
Jun 1, 2026, 20:58 UTC
CEPI committed up to $50 million to Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based Bundibugyo ebolavirus vaccine candidate.
Source:
- arstechnica.com
Jun 1, 2026, 16:39 UTC
Moderna expanded its partnership with CEPI.
Source:

MRNA

Moderna's stock price reached a four-week high, with its latest gain at 8%.

The US Food and Drug Administration approved Moderna's mFLUSIVA, the first mRNA-based influenza vaccine, for adults aged 50 and older.

Moderna (MRNA) shares closed at $146.69, up 1.89% from the prior session, outperforming a 0.48% decline in the S&P 500, a 0.29% drop in the Dow and a 0.56% drop in the Nasdaq.

Moderna and Merck announced that a personalized mRNA cancer vaccine combined with an immunotherapy drug succeeded in a late-stage trial for skin cancer.

Bloomberg announced the initial list of confirmed speakers for the eighth Bloomberg New Economy Forum, to be held in New Delhi from October 13 to 15, 2026, under the theme "A World in Play: Defining the New Levers of Power."

Moderna shares jumped just over 8% on Friday, trading at $148.13 as of 11:45am ET, continuing a volatile stretch following a landmark Phase 3 cancer trial result announced in August.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) authorised Moderna's updated COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 XFG variant, for adults and children aged six months and above.

Moderna announced that its upgraded COVID-19 vaccine is expected to be available in the coming days.

Moderna announced a proposed private placement of $2.0 billion aggregate principal amount of Convertible Senior Notes due 2032, with an option for initial purchasers to buy up to an additional $300 million, to qualified institutional buyers.

The U.S. Food and Drug Administration approved a new mRNA-based flu vaccine from Moderna for adults aged 50 and older.

Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.

Moderna announced that its influenza vaccine MflusiVa will be available at select retailers in the coming weeks.

Moderna Inc. has started a Phase 1 clinical trial of an experimental Ebola vaccine targeting the strain causing the outbreak in the Democratic Republic of Congo.

Moderna announced the initiation of a Phase 1 clinical trial for its investigational mRNA vaccine mRNA-1469 against Bundibugyo ebolavirus, with first participants vaccinated in Canada.

Moderna announced that its seasonal influenza vaccine candidate mFLUSIVA has an anticipated FDA approval decision date of August 5, 2026.

Moderna reported second quarter 2026 financial results with revenue of $0.1 billion, a GAAP net loss of $0.8 billion, and GAAP EPS of -$1.97.

Moderna announced that its norovirus vaccine candidate mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis and the company is preparing to enroll an additional cohort.

Arbutus Biopharma received a first payment from a settlement agreement with Moderna.

Moderna opens a new innovation centre in Harwell with a £1 billion UK R&D investment commitment over the next 10 years.

Moderna secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.

Michael McDonnell was appointed as a Class II director of Moderna, Inc. and a member of its Audit Committee, effective July 8, 2026.

The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 that Moderna's mFLUSIVA (mRNA-1010) has a favorable benefit-risk profile for adults aged 50 and older.

The FDA advisory committee recommended Moderna's flu vaccine for approval.

The FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously in favor of the benefit-risk profile of Moderna's investigational seasonal influenza vaccine mRNA-1010.

Moderna expressed interest in investing in production facilities in Germany, potentially acquiring plants that BioNTech plans to close.

Moderna appointed a new chief commercial officer and widened its president's role to oversee certain franchises.

Moderna launched Moderna Direct, an eCommerce platform powered by FFF Enterprises, to provide an enhanced ordering experience for its customers.

CEPI committed up to $50 million to Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based Bundibugyo ebolavirus vaccine candidate.

Moderna expanded its partnership with CEPI.